HG 153
Alternative Names: HG-153Latest Information Update: 18 Sep 2023
Price :
$50 *
At a glance
- Originator HitGen
- Class Antineoplastics; Small molecules
- Mechanism of Action Menin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 24 Aug 2023 Preclinical trials in acute myeloid leukemia in China (PO) prior to August 2023 (HitGen pipeline, August 2023)
- 24 Aug 2023 Preclinical trials in Precursor cell lymphoblastic leukaemia-lymphoma in China (PO) prior to August 2023 (HitGen pipeline, August 2023)
- 30 Dec 2022 HitGen has patent pending for "menin inhibitor and use thereof" in the world (WO 202 312 592 8A1)